NCM
ABEO icon

Nantahala Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Nantahala Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.5M Buy
5,013,052
+50,000
+1% +$250K 0.83% 33
2025
Q4 		$26.2M Buy
4,963,052
+398,387
+9% +$2.01M 0.86% 26
2025
Q3 		$24.1M Buy
4,564,665
+195,000
+4% +$1.24M 0.84% 25
2025
Q2 		$24.8M Buy
4,369,665
+859,815
+24% +$4.89M 0.97% 18
2025
Q1 		$16.7M Sell
3,509,850
-19,364
-0.5% -$105K 0.66% 25
2024
Q4 		$19.7M Buy
3,529,214
+96,577
+3% +$594K 0.84% 24
2024
Q3 		$21.7M Sell
3,432,637
-37,400
-1% -$195K 1.1% 21
2024
Q2 		$14.7M Buy
3,470,037
+1,159,397
+50% +$5.91M 0.86% 21
2024
Q1 		$16.8M Buy
2,310,640
+60,388
+3% +$383K 0.96% 21
2023
Q4 		$11.3M Sell
2,250,252
-47,542
-2% -$209K 0.67% 32
2023
Q3 		$9.67M Buy
2,297,794
+895,914
+64% +$3.39M 0.83% 29
2023
Q2 		$5.65M Sell
1,401,880
-26,795
-2% -$93.7K 0.55% 48
2023
Q1 		$4.03M Buy
1,428,675
+1,155,944
+424% +$3.02M 0.31% 57
2022
Q4 		$4.19M Buy
+272,731
New +$1.02M 0.27% 54

Other funds holding ABEO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nantahala Capital Management's ABEO Position: Q1 2026 in Review

Nantahala Capital Management increased its Abeona Therapeutics (ABEO) stake by 1% in Q1 2026, buying an estimated $250K and bringing the position to 5,013,052 shares worth $22.5M. The position accounts for 0.83% of the portfolio, ranked #33.

Nantahala Capital Management first reported a position in ABEO in Q4 2022 and has held it in 14 quarters since. The position peaked at $26.2M in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Nantahala Capital Management held 5,013,052 shares of Abeona Therapeutics worth $22.5M as of Q1 2026.
  • Nantahala Capital Management bought 50,000 Abeona Therapeutics shares in Q1 2026, an estimated $250K.
  • Abeona Therapeutics made up 0.83% of Nantahala Capital Management's portfolio in Q1 2026, its #33 holding.
  • Nantahala Capital Management first reported a position in Abeona Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Nantahala Capital Management's Abeona Therapeutics position peaked at $26.2M in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.